Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue

International Journal of Gynecology and Obstetrics

Volumn 67, Issue 1, 1999, Pages 33-38

  Bernardes Jr , J R M ^a   Nonogaki, S ^a   Seixas, M T ^a   Rodrigues De Lima, G ^a   Baracat, E C ^a   Gebrim, L H ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Breast; PCNA; Premenopause; Sex hormones; Tamoxifen

Indexed keywords

CYCLINE; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PLACEBO; PROGESTERONE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN;

ADOLESCENT; ADULT; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; BREAST FIBROADENOMA; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HISTOLOGY; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; ORAL DRUG ADMINISTRATION; PARTIAL MASTECTOMY; PREMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032727095     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(99)00092-2     Document Type: Article

References (23)

1. Leis HP. The role of tamoxifen in prevention and treatment of benign and malignant breast lesions: a chemopreventive. Int Surg 1993;78:176-182.
2. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991;83(20):1450-1459.
3. EBCTCG-Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-1467.
4. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowset M et al. Interim analyses of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
5. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90(18):1371-1388.
6. Facina G, Rodrigues de Lima G, Simões MJ, Novo NF, Gebrim LH. Estrogenic activity of tamoxifen on normal mammary parenchyma in the luteal phase of the menstrual cycle. Int J Gynecol Obstet 1997;56:19-24.
7. Uehara J, Nazário ACP, Rodrigues de Lima G, Simões MJ, Juliano Y, Gebrim LH. Effects of tamoxifen on the breast in the luteal phase of the menstrual cycle. Int J Gynecol Obstet 1998;62:77-82.
8. Quadros LGA. Evaluation of the proliferative activity in normal human breast epithelium during the administration of tamoxifen. Doctor's thesis, Federal University of São Paulo, 1996.
9. Celis EJ, Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci 1985;82:3262-3266.
10. Hall PA, Levison DA, Woods AL, Yu CCW, Kellock DB, Watkins JA et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162: 285-294.
11. Speroff L, Glass RH, Kase NG. Investigação do casal estéril. In: Endocrinologia ginecológica clínica e infertilidade, 4th ed. São Paulo: Manole, 1991:601-640.
12. Neter J, Wasferman W, Kutner MH. Applied linear statistical models: regression, analyses of variance and experimental designs, 3rd ed. Homewood: Richard D. Irwing, 1990:1181.
13. Bussab WO, Morettin PA. Estatística básica - métodos quantitatívos, 4th ed. São Paulo: Atual, 1987:321.
14. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995;13(2):513-529.
15. Fentiman IS, Caleffi M, Hamed H, Chaudary MA. Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial. Br J Surg 1988;75(9):845-846.
16. Walker KJ, Price-Thomas JM, Candlish W, Nicholson RI. Influence of the antioestrogen tamoxifen on normal breast tissue. Br J Cancer 1991;64:764-768.
17. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 1991;83:1488-1491.
18. Groom GV, Griffths K. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicule-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocr 1976;70:421-428.
19. Sherman BM, Chapler FK, Crickard K, Wycoff D. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 1979;64(2):398-404.
20. Senior BE, Cawood ML, Oakey RE, McKiddie JM, Siddle DR. A comparison of the effects of clomiphene and tamoxifen treatment on the concentrations of oestradiol and progesterone in the peripheral plasma of infertile women. Clin Endocrinol 1978;8(5):381-389.
21. Athanassiou IK, Ntalles K, Gogas J, Markopoulos C, Terzaki VA, Athanassiou P et al. Sex hormones in postmenopausal women with breast cancer on tamoxifen. Hormone Res 1997;47:116-120.
22. Maltoni C, Minardi F, Belpoggi F, Pinto C, Lenzi A. Experimental results on the chemopreventive and side effects of tamoxifen using a human-equivalent animal model. In: Maltoni C, Soffritti M, Davis W, editors. The scientific bases of cancer chemoprevention. Amsterdam: Elsevier Sciences, 1996:197-217.
23. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and non-reprodutive tissues in ovariectomized rats. FASEB J 1996;10:905-912.